CORONA Remedies Q1FY27 Revenue Up 21.9% to ₹422.4 Cr, PAT Grows 30.1%
CORONA Remedies reported Q1FY27 revenue of ₹422.4 Cr, a 21.9% Y-o-Y growth. PAT increased by 30.1% to ₹60.1 Cr with margins at 14.2%. The company is the fastest growing in IPM for six months and ranks 26th. A new EU-GMP approved Female Hormone Facility was inaugurated on June 30, 2026.
Significant revenue and profit growth, market outperformance, and the launch of a new EU-GMP approved facility are material events that are likely to have a high impact on the company's performance and investor perception.
The company reported strong year-on-year growth in revenue and profit after tax, along with improved margins and market rank. The inauguration of a new manufacturing facility also contributes positively.
CORONA Remedies Limited announced its unaudited standalone and consolidated financial results for the first quarter and three months ended June 30, 2026. The company reported a revenue growth of 21.9% year-on-year, reaching ₹422.4 crore. Profit After Tax (PAT) saw a significant increase of 30.1% year-on-year, standing at ₹60.1 crore. PAT margins improved by 90 basis points to 14.2%.
The company also highlighted its strong performance against the Indian Pharmaceutical Market (IPM), being the fastest-growing company among the top 30 IPM companies for the last six consecutive months as per MAT June 2026, outperforming the market by 1.9 times. CORONA has moved up 3 places in market rank to 26th as per MAT June 2026. The company maintains a 5th rank in the Gynaecology therapy segment.
Key developments include the inauguration and commercialization of its EU-GMP approved Female Hormone Manufacturing Facility in Ahmedabad on June 30, 2026. The integration of the acquired brand 'Wokadine' has also been initiated from supply and distribution perspectives.
Commenting on the results, Mr. Nirav K. Mehta, Managing Director & CEO, stated that the performance reflects a commitment to consistent growth through operational excellence and brand building. The company aims to focus on core therapies like Women's Healthcare, Cardio-diabetes, Pain Management, and Urology, while also strengthening its presence in the Infertility and Biosimilar segments.
The Board meeting commenced at 3:00 p.m. and concluded at 4:00 p.m.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.